Viking Therapeutics, Inc.
VKTX
$33.80
-$0.64-1.86%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -211.75% | -268.33% | -227.05% | -139.43% | -77.32% |
| Total Depreciation and Amortization | 7.14% | 5.74% | 24.57% | 44.19% | 41.89% |
| Total Amortization of Deferred Charges | -91.67% | -64.44% | -40.43% | -16.67% | 29.73% |
| Total Other Non-Cash Items | 26.27% | 109.43% | 154.54% | 117.42% | 160.77% |
| Change in Net Operating Assets | 1,412.08% | 558.45% | 423.16% | -213.42% | -143.27% |
| Cash from Operations | -174.32% | -154.00% | -217.45% | -202.46% | -112.02% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 188.82% | 1,195.76% | 161.69% | 151.96% | 124.57% |
| Cash from Investing | 188.82% | 1,195.76% | 161.69% | 151.96% | 124.57% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2,441.02% | 1,201.17% | -88.32% | -99.64% | -99.33% |
| Repurchase of Common Stock | -- | -- | -- | 100.00% | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2,441.02% | 1,201.17% | -87.52% | -99.62% | -99.28% |
| Foreign Exchange rate Adjustments | 116.67% | 107.07% | 94.59% | -279.17% | -80.95% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,017.60% | 150.86% | 582.43% | 280.10% | 60.81% |